Sofinnova Investments

The firm sources therapeutic-company opportunities across the United States and Europe, leveraging a network built since its 1976 founding in Paris and its later independent U.S. presence. Board members and investment professionals originate deals through academic medical centers, biotech clusters, and relationships with serial life-science entrepreneurs. The dual-continent footprint gives it visibility into both FDA-oriented and EMA-oriented clinical-stage programs.

Yes, the firm operates a public-equity strategy focused on global therapeutics, complementing its core venture-capital activity. The public-equity effort invests in biopharmaceutical companies that are already listed, while the venture funds focus on private, clinical-stage drug developers.

Sofinnova Investments concentrates on late-preclinical and clinical-stage therapeutics and has been primarily focused on drugs over the last decade. The firm does not list medical-device, diagnostics, or healthcare-services companies among its active portfolio, steering its capital toward areas such as oncology, neurology, ophthalmology, and rare disease.

Sofinnova reports having funded 118 portfolio companies. Outcomes include initial public offerings — such as Seaport Therapeutics and BioAge Labs — and strategic acquisitions by large pharmaceutical companies including AstraZeneca, Roche, and Bristol Myers Squibb. The firm does not publicly disclose internal rates of return or distributed-to-paid-in multiples.